AMGN vs GILD — Key Metrics

Metric AMGN (AMGEN INC) GILD (GILEAD SCIENCES INC)
Price443.89168.98
Market Cap240.11 Billion209.59 Billion
P/E (TTM)25.54-54.51
P/B (Quarterly)18.03316.235
P/S (TTM)6.176.76
Net Profit Margin (TTM)24.1-12.5
Gross Margin (TTM)70.979.9
ROE (TTM)85.6-21.7
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

AMGEN INC
vs
 
GILEAD SCIENCES INC
 
AMGEN INC
vs
 
GILEAD SCIENCES INC
Performance Comparison
AI Model Recommendation
AMGN · AMGEN INC

Outperform

38
UnderperformOutperform
GILD · GILEAD SCIENCES INC

Outperform

57
UnderperformOutperform
Recommendation Summary

Both stocks are projected to outperform the market over the next year. If you have to make a choice, Upfront Recommendation: GILD.

Financial Metrics
Prices delayed ~15 min
AMGN Metrics GILD
$443.89 Price $168.98
— Market Capitalization —
6.17 Price to Sales 6.76
25.06 Price to FCF Ratio 15.21
8.7 Price to Gross Profit 8.46
30.63 Price to R&D 33.12
6.99 Price to Current Assets 12.66

AMGN vs GILD at a glance

Amgen INC (AMGN) and Gilead Sciences INC (GILD) are both Drug Manufacturers - General companies in the Healthcare sector. They are similar in size: $240.1 billion and $209.6 billion in market value.

On trailing-twelve-month figures, AMGN trades at 6.2 times trailing sales and GILD at 6.8; net profit margins are 24.1% and -12.5%.

The Upfront Investment model currently rates both Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.